IPO
-
Star Health Insurance IPO Review- Operating in a sweet spot with long term structural growth
To augment the company’s capital base and insolvency level.
-
PayTm IPO Review- Yet to establish viable business model
50% of the offer value will be paid to existing shareholders.
-
PolicyBazaar IPO Review: Taking advantage of Platform boom, high risk high return?
PB Fintech is India’s leading online platform for insurance and lending products.
-
Nykaa IPO Review- Well placed for growth; Tough to quantify value
90% of the proceeds of the IPO will go to existing shareholders.
-
Aditya Birla Sun Life AMC IPO Review – Large company operating in a growth market
The company will not receive any proceeds from the offer.
-
Sansera Engineering IPO Review- Wrong time in not a right sector
Sansera Engineering Limited is an engineering-led integrated manufacturer of complex and critical precision engineered components across the automotive and non-automotive sectors, they…
-
Vijaya Diagnostic IPO Review: Taking advantage of market favouritism
Vijaya Diagnostic Centre Limited (VDC) was incorporated on June 5, 2002. VDC is one of the leading integrated diagnostic chains in Telegana.
-
CarTrade IPO Review: With no clear winner, valuation too demanding
Cartrade is a multi-channel auto platform with coverage and presence across vehicle types and value-added services.
-
Nuvoco Vistas IPO Review: Beneficiary of Infrastructure spends
Nuvoco Vista Corporation Limited (Nuvoco) is promoted by Dr. Karsanbhai K. Patel of Nirma Group.
-
Windlas Biotech IPO Review: Scale of operations raises doubts on profitability
Incorporated in February 2001, Windlas Biotech Limited (“Windlas”) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue.
-
Devyani International IPO Review: Fast Growing QSR Model
Incorporated in December 1991, Devyani International Limited is the largest franchisee of Yum Brands in India and is among the largest chain operators of quick-service restaurants (“QSR”) in India on a non-exclusive…
-
Glenmark Life Sciences IPO Review: Taking advantage of API boom
Glenmark Life Sciences Limited (“GLS”) is a Rs. 2,000 Cr developer and manufacturer of select active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas.
